Homelessness and adherence to antiretroviral therapy among a cohort of HIV-infected injection drug users

Anita Palepu, M-J Milloy, Thomas Kerr, Ruth Zhang, Evan Wood, Anita Palepu, M-J Milloy, Thomas Kerr, Ruth Zhang, Evan Wood

Abstract

Homelessness is prevalent among HIV-infected injection drug users (IDU) and may adversely affect access and adherence to antiretroviral therapy (ART). There are limited descriptions of the effect of homelessness on adherence to ART in long-term cohorts of HIV-infected IDU. We used data from a community-recruited prospective cohort of HIV-infected IDU, including comprehensive ART dispensation records, in a setting where HIV care is free. We examined the relationship between the homelessness measured longitudinally, and the odds of ≥95% adherence to ART using generalized estimating equations logistic regression modeling adjusting for sociodemographics, drug use, and clinical variables. Between May 1996 and September 2008, 545 HIV-infected IDU were recruited and eligible for the present study. The median follow-up duration was 23.8 months (IQR 8.5-91.6 months) contributing 2,197 person-years of follow-up. At baseline, homeless participants were slightly younger (35.8 vs. 37.9 years, p = 0.01) and more likely to inject heroin at least daily (37.1% vs. 24.6%. p = 0.004) than participants who had housing. The multivariate model revealed that homelessness (adjusted odds ratio [AOR] 0.66; 95% CI: 0.53-0.84) and frequent heroin use (AOR 0.40; 95% CI: 0.30-0.53) were significantly and negatively associated with ART adherence, whereas methadone maintenance was positively associated (AOR 2.33; 95% CI: 1.86-2.92). Sub-optimal ART adherence was associated with homelessness and daily injection heroin use among HIV-infected IDU. Given the survival benefit of ART, it is critical to develop and evaluate innovative strategies such as supportive housing and methadone maintenance to address these risk factors to improve adherence.

Figures

FIGURE 1
FIGURE 1
Multivariable logistic regression model using GEE of factors associated with 95% antiretroviral therapy adherence.

References

    1. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. NEJM. 1997;337(11):725–33. doi: 10.1056/NEJM199709113371101.
    1. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362(9377):22–9. doi: 10.1016/S0140-6736(03)13802-0.
    1. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA. 2001;286(20):2568–77. doi: 10.1001/jama.286.20.2568.
    1. Palella FJ, Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. NEJM. 1998;338(13):853–60. doi: 10.1056/NEJM199803263381301.
    1. Vlahov D, Celentano DD. Access to highly active antiretroviral therapy for injection drug users: adherence, resistance, and death. Cad Saúde Pública. 2006;22(4):705–18. doi: 10.1590/S0102-311X2006000400002.
    1. Lert F, Kazatchkine MD. Antiretroviral HIV treatment and care for injecting drug users: an evidence-based overview. Int J Drug Policy. 2007;18(4):255–61. doi: 10.1016/j.drugpo.2007.05.002.
    1. Wood E, Montaner JSG, Tyndall MW, Schechter MT, O'Shaughnessy MV, Hogg RS. Prevalence and correlates of untreated human immunodeficiency virus type 1 infection among persons who have died in the era of modern antiretroviral therapy. J Infect Dis. 2003;188(8):1164–70. doi: 10.1086/378703.
    1. Strathdee SA, Palepu A, Cornelisse PG, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA. 1998;280(6):547–9. doi: 10.1001/jama.280.6.547.
    1. Lucas GM, Griswold M, Gebo KA, Keruly J, Chaisson RE, Moore RD. Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy. Am J Epidemiol. 2006;163(5):412–20. doi: 10.1093/aje/kwj059.
    1. Wood E, Montaner JS, Yip B, et al. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ. 2003;169(7):656–61.
    1. Lucas GM, Gebo KA, Chaisson RE, Moore RD. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS. 2002;16(5):767–74. doi: 10.1097/00002030-200203290-00012.
    1. Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2001;27(3):251–9. doi: 10.1097/00042560-200107010-00006.
    1. Krusi A, Wood E, Montaner J, Kerr T. Social and structural determinants of HAART access and adherence among injection drug users. Int J Drug Policy. 2010;21(1):4–9. doi: 10.1016/j.drugpo.2009.08.003.
    1. Wood E, Kerr T, Tyndall MW, Montaner JS. A review of barriers and facilitators of HIV treatment among injection drug users. AIDS. 2008;22(11):1247–56. doi: 10.1097/QAD.0b013e3282fbd1ed.
    1. Douaihy AB, Stowell KR, Bui T, Daley D, Salloum I. HIV/AIDS and homelessness, part 2: treatment issues. AIDS Read. 2005;15(11):604–18.
    1. Wolitski RJ, Kidder DP, Fenton KA. HIV, homelessness, and public health: critical issues and a call for increased action. AIDS Behav. 2007;11(6 Suppl):167–71. doi: 10.1007/s10461-007-9277-9.
    1. Galea S, Rudenstine S, Vlahov D. Drug use, misuse, and the urban environment. Drug Alcohol Rev. 2005;24(2):127–36. doi: 10.1080/09595230500102509.
    1. Kim C, Kerr T, Li K, et al. Unstable housing and hepatitis C incidence among injection drug users in a Canadian setting. BMC Public Health. 2009;9(1):270. doi: 10.1186/1471-2458-9-270.
    1. Palepu A, Strathdee SA, Hogg RS, et al. The social determinants of emergency department and hospital use by injection drug users in Canada. J Urban Health. 1999;76(4):409–18. doi: 10.1007/BF02351499.
    1. Strathdee SA, Patrick DM, Currie SL, et al. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS. 1997;11(8):F59–65. doi: 10.1097/00002030-199708000-00001.
    1. Culhane DP, Gollub E, Kuhn R, Shpaner M. The co-occurrence of AIDS and homelessness: results from the integration of administrative databases for AIDS surveillance and public shelter utilisation in Philadelphia. J Epidemiol Community Health. 2001;55(7):515–20. doi: 10.1136/jech.55.7.515.
    1. Hwang SW. Mortality among men using homeless shelters in Toronto, Ontario. JAMA. 2000;283(16):2152–7. doi: 10.1001/jama.283.16.2152.
    1. Hwang SW, Lebow JM, Bierer MF, O'Connell JJ, Orav EJ, Brennan TA. Risk factors for death in homeless adults in Boston. Arch Intern Med. 1998;158(13):1454–60. doi: 10.1001/archinte.158.13.1454.
    1. Hwang SW, Orav EJ, O'Connell JJ, Lebow JM, Brennan TA. Causes of death in homeless adults in Boston. Ann Intern Med. 1997;126(8):625–8.
    1. Cheung AM, Hwang SW. Risk of death among homeless women: a cohort study and review of the literature. CMAJ. 2004;170(8):1243–7. doi: 10.1503/cmaj.1031167.
    1. Morrison DS. Homelessness as an independent risk factor for mortality: results from a retrospective cohort study. Int J Epidemiol. 2009;38(3):877–83. doi: 10.1093/ije/dyp160.
    1. Aidala AA, Lee G, Abramson DM, Messeri P, Siegler A. Housing need, housing assistance, and connection to HIV medical care. AIDS Behav. 2007;11(6 Suppl):101–15. doi: 10.1007/s10461-007-9276-x.
    1. Leaver CA, Bargh G, Dunn JR, Hwang SW. The effects of housing status on health-related outcomes in people living with HIV: a systematic review of the literature. AIDS Behav. 2007;11(6 Suppl):85–100. doi: 10.1007/s10461-007-9246-3.
    1. Kidder DP, Wolitski RJ, Campsmith ML, Nakamura GV. Health status, health care use, medication use, and medication adherence among homeless and housed people living with HIV/AIDS. Am J Public Health. 2007;97(12):2238–45. doi: 10.2105/AJPH.2006.090209.
    1. Bangsberg DR, Hecht FM, Clague H, et al. Provider assessment of adherence to HIV antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;26(5):435–42. doi: 10.1097/00042560-200104150-00005.
    1. Wood E, Hogg RS, Bonner S, et al. Staging for antiretroviral therapy among HIV-infected drug users. JAMA. 2004;292(10):1175–7. doi: 10.1001/jama.292.10.1175-b.
    1. Wood E, Hogg RS, Lima VD, et al. Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA. 2008;300(5):550–4. doi: 10.1001/jama.300.5.550.
    1. Wood E, Hogg RS, Yip B, et al. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 × 10(9) cells/L. Ann Intern Med. 2003;139(10):810–6.
    1. Palepu A, Tyndall MW, Joy R, et al. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend. 2006;84(2):188–94. doi: 10.1016/j.drugalcdep.2006.02.003.
    1. Low-Beer S, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr. 2000;23(4):360–1. doi: 10.1097/00042560-200004010-00016.
    1. Palepu A, Tyndall M, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS. Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use. J Acquir Immune Defic Syndr. 2003;32(5):522–6. doi: 10.1097/00126334-200304150-00009.
    1. Uhlmann S, Milloy MJ, Kerr T, et al. Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users. Addiction. 2010;105(5):907–13. doi: 10.1111/j.1360-0443.2010.02905.x.
    1. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42:121–30. doi: 10.2307/2531248.
    1. Liang KY, Zeger SY. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13–22. doi: 10.1093/biomet/73.1.13.
    1. Maldonado G, Greenland S. Simulation study of confounder-selection strategies. Am J Epidemiol. 1993;138(11):923–36.
    1. Marshall BD, Kerr T, Shoveller JA, Patterson TL, Buxton JA, Wood E. Homelessness and unstable housing associated with an increased risk of HIV and STI transmission among street-involved youth. Health Place. 2009;15(3):753–60. doi: 10.1016/j.healthplace.2008.12.005.
    1. Lima V, Fernandes K, Rachlis B, Druyts E, Montaner J, Hogg R. Migration adversely affects antiretroviral adherence in a population-based cohort of HIV/AIDS patients. Soc Sci Med. 2009;68(6):1044–9. doi: 10.1016/j.socscimed.2008.12.043.
    1. Wood E, Montaner JS, Yip B, et al. Adherence to antiretroviral therapy and CD4 T-cell count responses among HIV-infected injection drug users. Antivir Ther. 2004;9(2):229–35.
    1. Lucas GM, Chaudhry A, Hsu J, et al. Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: a randomized trial. Ann Intern Med. 2010;152(11):704–11.
    1. Avants SK, Margolin A, Warburton LA, Hawkins KA, Shi J. Predictors of nonadherence to HIV-related medication regimens during methadone stabilization. Am J Addict American. 2001;10(1):69–78. doi: 10.1080/105504901750160501.
    1. Palepu A, Horton NJ, Tibbetts N, Meli S, Samet JH. Uptake and adherence to highly active antiretroviral therapy among HIV-infected people with alcohol and other substance use problems: the impact of substance abuse treatment. Addiction. 2004;99(3):361–8. doi: 10.1111/j.1360-0443.2003.00670.x.
    1. Hwang SW, O'Connell JJ, Lebow JM, Bierer MF, Orav EJ, Brennan TA. Health care utilization among homeless adults prior to death. J Health Care Poor Underserved. 2001;12(1):50–8.
    1. Walley AY, Cheng DM, Libman H, et al. Recent drug use, homelessness and increased short-term mortality in HIV-infected persons with alcohol problems. AIDS. 2008;22(3):415–20. doi: 10.1097/QAD.0b013e3282f423f8.
    1. Kushel MB, Colfax G, Ragland K, Heineman A, Palacio H, Bangsberg DR. Case management is associated with improved antiretroviral adherence and CD4+ cell counts in homeless and marginally housed individuals with HIV infection. Clin Infect Dis. 2006;43(2):234–42. doi: 10.1086/505212.
    1. Macalino GE, Hogan JW, Mitty JA, et al. A randomized clinical trial of community-based directly observed therapy as an adherence intervention for HAART among substance users. AIDS. 2007;21(11):1473–7. doi: 10.1097/QAD.0b013e32811ebf68.
    1. Tyndall MW, McNally M, Lai C, et al. Directly observed therapy programmes for anti-retroviral treatment amongst injection drug users in Vancouver: access, adherence and outcomes. Int J Drug Policy. 2007;18(4):281–7. doi: 10.1016/j.drugpo.2006.11.009.
    1. Altice FL, Maru DS, Bruce RD, Springer SA, Friedland GH. Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial. Clin Infect Dis. 2007;45(6):770–8. doi: 10.1086/521166.
    1. Conway B, Prasad J, Reynolds R, et al. Directly observed therapy for the management of HIV-infected patients in a methadone program. Clin Infect Dis. 2004;38(Suppl 5):S402–8. doi: 10.1086/421404.
    1. Maru DS, Bruce RD, Walton M, Springer SA, Altice FL. Persistence of virological benefits following directly administered antiretroviral therapy among drug users: results from a randomized controlled trial. J Acquir Immune Defic Syndr. 2009;50(2):176–81. doi: 10.1097/QAI.0b013e3181938e7e.
    1. Kidder DP, Wolitski RJ, Royal S, et al. Access to housing as a structural intervention for homeless and unstably housed people living with HIV: rationale, methods, and implementation of the housing and health study. AIDS Behav. 2007;11(6 Suppl):149–61. doi: 10.1007/s10461-007-9249-0.
    1. Wolitski RJ, Kidder DP, Pals SL, et al. Randomized trial of the effects of housing assistance on the health and risk behaviors of homeless and unstably housed people living with HIV. AIDS Behav. 2010;14(3):493–503. doi: 10.1007/s10461-009-9643-x.
    1. Buchanan D, Kee R, Sadowski LS, Garcia D. The health impact of supportive housing for HIV-positive homeless patients: a randomized controlled trial. Am J Public Health. 2009;99(Suppl 3):S675–80. doi: 10.2105/AJPH.2008.137810.
    1. Culhane D, Metraus S, Hadley T. Public service reductions associated with placement of homeless persons with severe mental illness in supportive housing. Hous Policy Debate. 2002;13:107–62.
    1. Tsemberis S, Gulcur L, Nakae M. Housing First, consumer choice, and harm reduction for homeless individuals with a dual diagnosis. Am J Public Health. 2004;94(4):651–6. doi: 10.2105/AJPH.94.4.651.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren